Adiponectin - An adipokine with unique metabolic properties

Nephrology Dialysis Transplantation

Volumn 22, Issue 4, 2007, Pages 981-988

  Wiecek, Andrzej ^a   Adamczak, Marcin ^a   Chudek, Jerzy ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Adipocytes; Adipokines; Adiponectin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ADIPONECTIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; INDAPAMIDE; LOSARTAN; RAMIPRIL; RILMENIDINE; RIMONABANT; TELMISARTAN; TEMOCAPRIL; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; DISEASE FREE SURVIVAL; EDITORIAL; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; SMALL FOR DATE INFANT; VASCULAR SMOOTH MUSCLE; WEIGHT REDUCTION;

ADIPONECTIN; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DISEASES; RISK FACTORS;

EID: 34047161580     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl814     Document Type: Editorial

References (100)

1. Chudek J, Adamczak M, Nieszporek T, Wiecek A. The adipose tissue as an endocrine organ - a nephrologists' perspective. Contrib Nephrol 2006; 151: 70-90
2. Wiecek A, Kokot F, Chudek J, Adamczak M. The adipose tissue - a novel endocrine organ of interest to the nephrologist. Nephrol Dial Transplant 2002; 17: 191-195
3. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: Action, regulation and association to insulin sensitivity. Obes Rev 2005; 6: 13-21
4. Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 2004; 219: 9-15
5. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83
6. Peake PW, Kriketos AD, Denyer GS, Campbell LV, Charlesworth JA. The postprandial response of adiponectin to a high-fat meal in normal and insulin-resistant subjects. Int J Obes Relat Metab Disord 2003; 27: 657-662
7. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-451
8. Wang B, Trayhurn P. Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch 2006; 452: 418-427
9. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: Role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005; 25: 2062-2068
10. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808
11. Fain JN, Bahouth SW, Madan AK. TNF alpha release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord 2004; 28: 616-622
12. Halleux CM, Takahashi M, Delporte ML et al. Secretion and regulation of ApM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 2001; 288: 1102-1107
13. Hotto K, Funahashi T, Arita Y et al. Plasma concentration of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599
14. Iwashima Y, Katsuya T, Ishikawa K et al. Association of hypoadiponectinemia with smoking habit in men. Hypertension 2005; 45: 1094-1100
15. Dzielińska Z, Januszewicz A, Wiecek A et al. Decreased plasma concentration of a novel anti-inflammatory protein-adiponectin-in hypertensive men with coronary artery disease. Thromb Res 2003; 110: 365-369
16. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003; 16: 72-75
17. Yang W, Chuang L. Human genetics of adiponectin in the metabolic syndrome. J Mol Med 2006; 84: 112-121
18. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769
19. Hattori Y, Suzuki M, Hattori K, Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 2003; 46: 1543-1549
20. Rasmussen MS, Lihn AS, Pedersen SB, Bruun JM, Rasmussen M, Richelsen B. Adiponectin receptors in human adipose tissue: Effects of obesity, weight loss, and fat depots. Obesity 2006; 14: 28-35
21. Debard C, Laville M, Berbe V et al. Expression of key genes of fatty acid oxidation, including adiponectin receptors in skeletal muscle of type 2 diabetic patients. Diabetologia 2004; 47: 917-925
22. Kim MJ, Maachi M, Debard C et al. Increased adiponectin receptor-1 expression in adipose tissue of impaired glucose-tolerant obese subjects during weight loss. Eur J Endocrinol 2006; 155: 161-165
23. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476
24. Ouchi N, Kihara S, Arita Y et al. Adipocyte - derived plasma protein, adiponectin, suppress lipid accumulation and class A receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-1063
25. Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 2004; 315: 264-271
26. Magalang UJ, Rajappan R, Hunter MG et al. Adiponectin inhibits superoxide generation by human neutrophils. Antioxid Redox Signal 2006; 8: 2179-2186
27. Arita Y, Kihara S, Ouchi N et al. Adipocyte-derived plasma protein, adiponectin, acts as a platelet-derived growth-factor-BB-binding protein and regulates growth factor-induced common post-receptor signal in vascular smooth muscle cell. Circulation 2002; 105: 2893-2898
28. Wang Y, Lam KS, Xu JY et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 2005; 280: 18341-18347
29. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates nitric oxide production in vascular endothelial cells. J Biol Chem 2003; 278: 45021-45026
30. Ouchi N, Ohishi M, Kihara S et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231-234
31. Okamoto Y, Kihara S, Ouchi N et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767-2670
32. Yamauchi T, Kamon J, Waki H et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278: 2461-2468
33. Kumada M, Kihara S, Ouchi N et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004; 109: 2046-2049
34. Shibata R, Sato K, Pimentel DR et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005; 11: 1096-1103
35. Shibata R, Ouchi N, Sato K et al. Adiponectin regulates myocardial remodelling after myocardial infarction. J Hypertens 2006; 24 [Suppl 6]: 80
36. Shibata R, Ouchi N, Kihara S, Sato K, Funahashi T, Walsh K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J Biol Chem 2004; 279: 28670-28674
37. Yang H, Zhang R, Mu H, Li M, Yao Q, Chen C. Adiponectin promotes endothelial cell differentiation from human peripheral CD14+ monocytes in vitro. J Cell Mol Med 2006; 10: 459-469
38. Liao Y, Takashima S, Maeda N et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 2005; 67: 705-713
39. Shibata R, Ouchi N, Ito M et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004; 10: 1384-1389
40. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141
41. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 14: 1730-1737
42. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54: 534-539
43. Cavusoglu E, Ruwende C, Chopra V et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Eart J 2006; 27: 2300-2309
44. von Eynatten M, Schneider JG, Humpert PM et al. Serum adiponectin level are an independent predictor of the extent of coronary artery disease in men. J Am Coll Cardiol 2006; 46: 2124-2126
45. Otsuka F, Sugiyama S, Kojima S et al. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol 2006; 48: 1155-1162
46. Nilsson PM, Engstrom G, Hedblad B et al. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol 2006; 26: 2758-2762
47. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and metabolic syndrome. J Clin Invest 2006; 116: 1784-1792
48. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946
49. Ceddia RB, Somwar R, Maida A, Fang X, Bikopoulos G, Sweeney G. Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia 2005; 48: 132-139
50. Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res 2005; 46: 1369-1379
51. Hara K, Horikoshi M, Yamauchi T et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006; 29: 1357-1362
52. Waki H, Yamauchi T, Kamon J et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 278: 40352-40363
53. Hotta K, Funahashi T, Bodkin NL et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50: 1126-1133
54. Spranger J, Kroke A, Mohlig M et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-228
55. Snijder MB, Heine RJ, Seidell JC et al. Associations of Adiponectin Levels With Incident Impaired Glucose Metabolism and Type 2 Diabetes in Older Men and Women: The Hoorn Study. Diabetes Care 2006; 29: 2498-2503
56. Baýes B, Lauzurica R, Granada ML et al. Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. Transplantation 2004; 78: 26-30
57. Jaquet D, Deghmoun S, Chevenne D, Czernichow P, Lévy-Marchal C. Low serum adiponectin levels in subjects born small for gestational age: impact on insulin sensitivity. Int J Obes 2006; 30: 83-87
58. Adamczak M, Rzepka E, Chudek J, Wiecek A. Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol 2005; 62: 114-118
59. Mallamaci F, Zoccali C, Cuzzola F et al. Adiponectin in essential hypertension. J Nephrol 2002; 15: 507-511
60. Adamczak M, Czerwieńska B, Chudek J, Wiecek A. Renal extraction of circulating adiponectin in patients with renovascular hypertension. Acta Physiol Hung (in press)
61. Becker B, Kronenberg F, Kielstein JT et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: The mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16: 1091-1098
62. Saraheimo M, Forsblom C, Fagerudd J et al. Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 2005; 28: 1410-1414
63. Schalkwijk CG, Chaturvedi N, Schram MT, Fuller JH, Stehouwer CD. EURODIAB Prospective Complications Study Group. Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 2006; 91: 129-135
64. Adamczak M, Szotowska M, Chudek J, Karkoszka H, Cierpka L, Wiecek A. Plasma adiponectin concentration in patients after successful kidney transplantation - a single centre, observational study. Clinical Nephrology (submitted)
65. Ignacy W, Chudek J, Adamczak M et al. Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease - a follow-up study. Nephron Clin Pract 2005; 101: C18-c24
66. Marchlewska A, Stenvinkel P, Lindholm B et al. Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. Kidney Int 2004; 66: 46-50
67. Chudek J, Adamczak M, Karkoszka H et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 2003; 35: 2186-2189
68. Ouchi N, Kihara S, Funahashi T et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107: 671-674
69. Engeli S, Feldpausch M, Gorzelniak K et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003; 52: 942-947
70. Lee CT, Lee CH, Su Y, Chuang YC, Tsai TL, Cheni JB. The relationship between inflammatory markers, leptin and adiponectin in chronic hemodialysis patients. Int J Artif Organs 2004; 27: 835-841
71. Fasshauer M, Kralisch S, Klier M et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003; 301: 1045-1050
72. Kappes A, Loffler G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 2000; 32: 548-554
73. Maeda T, Taniguchi S, Sasaki H et al. Relationship between plasma adiponectin and cardiac function in patients with end-stage renal disease. J Hypertens 2006; 24 [Suppl 6]: 302
74. Adamczak M, Blach A, Kolonko A et al. Does relationship exist between plasma adiponectin concentration and left ventricular mass in kidney transplant patients? Nephrol Dial Transplant 2006; 21 [Suppl 4]: Iv276
75. Iwashima Y, Horio T, Suzuki Y et al. Adiponectin and renal function, and risk of cardiovascular disease. J Hypertens 2006; 24 [Suppl 6]: 354
76. Menon V, Li L, Wang X et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006; 16: 1091-1098
77. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
78. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169
79. Yang WS, Lee WJ, Funahashi T et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-3819
80. Esposito K, Pontillo A, Di Palo C et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. JAMA 2003; 289: 1799-1804
81. Valsamakis G, McTernan PG, Chetty R et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004; 53: 430-434
82. Yu JG, Javorschi S, Hevener AL et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 2968-2974
83. Hirose H, Kaqwai T, Yamamoto Y et al. Effects of pioglitasone on metabolic parameters, body fat distribution and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metab Clin Exp 2002; 51: 314-317
84. Phillips SA, Ciaraldi TP, Kong AP et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003; 52: 667-674
85. Yang WS, Jeng CY, Wu TJ et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376-380
86. Tonelli J, Li W, Kishore P et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 2004; 53: 1621-1629
87. Bobbert T, Rochlitz H, Wegewitz U et al. Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 2005; 54: 2712-2719
88. Pajvani U.B, Hawkins M, Combs TP et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152-12162
89. Furuhashi M, Ura N, Higashiura K et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-82
90. Koh K, Quon M, Han S et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005; 45: 1088-1093
91. Koh K, Quon M, Han S et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-3692
92. Koh K, Quon M, Han S, Chung WJ, Lee Y, Shin EK. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2005; 108: 96-100
93. Shmieder R, Schlaich M, Mimran A, Fauvel JP, Ruilope LM. The cytokine adiponectin is disparately influenced by telmisartan and ramipril in type 2 diabetes. J Hypertens 2006; 24 [Suppl 6]: 225
94. Fogari R, Derosa G, Mugellini A et al. Effect of valsartan and eprosartan on adiponectin, leptin and insulin sensitivity in hypertensive obese patients. J Hypertens 2006; 24 [Suppl 6]: 258
95. Nowak Ł, Adamczak M, Wiecek A. Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2005; 18: 1470-1475
96. Koh K, Quon M, Han S et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005; 45: 1649-1653
97. Despres JP, Golay A, Sjostrom L. Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134
98. Wiecek A, Piecha G, Chudek J, Adamczak M. Influence of different antihypertensive drugs on plasma adiponectin concentration in patients with essential hypertension. J Hypertens 2006; 24 [Suppl 6]: 356
99. Yenicesu M, Yilmaz MI, Caglar K et al. Blockade of the renin-angiotensin system increases plasma adiponectin concentration in type 2 diabetic patients with proteinuria. Nephron Clin Pract 2005; 99: C115-c121
100. Furuya R, Odamaki M, Kumagai H, Hishida A. Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients. Blood Purif 2006; 24: 445-450